This report aims to provide a comprehensive presentation of the global market for Non-Alcoholic Steatohepatitis (NASH) Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Non-Alcoholic Steatohepatitis (NASH) Treatment. This report contains market size and forecasts of Non-Alcoholic Steatohepatitis (NASH) Treatment in global, including the following market information:
Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Revenue, 2018-2023, 2024-2030, ($ millions)
Global top five companies in 2022 (%)
The global Non-Alcoholic Steatohepatitis (NASH) Treatment market was valued at US$ million in 2022 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Off-Label Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of Non-Alcoholic Steatohepatitis (NASH) Treatment include Allergan Plc (Tobira), Bristol Myers Squibb, Galmed Pharmaceuticals, Genfit SA, Gilead Sciences, Inc., Intercept Pharmaceuticals, Inc. and Zydus Cadila, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Non-Alcoholic Steatohepatitis (NASH) Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market, by Type, 2018-2023, 2024-2030 ($ millions)
Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Segment Percentages, by Type, 2022 (%)
Off-Label
Therapeutic
Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market, by Application, 2018-2023, 2024-2030 ($ millions)
Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Segment Percentages, by Application, 2022 (%)
Hospital Pharmacy
Online Provider
Retail Pharmacy
Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Region and Country, 2018-2023, 2024-2030 ($ Millions)
Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Non-Alcoholic Steatohepatitis (NASH) Treatment revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Non-Alcoholic Steatohepatitis (NASH) Treatment revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Allergan Plc (Tobira)
Bristol Myers Squibb
Galmed Pharmaceuticals
Genfit SA
Gilead Sciences, Inc.
Intercept Pharmaceuticals, Inc.
Zydus Cadila
Outline of Major Chapters:
Chapter 1: Introduces the definition of Non-Alcoholic Steatohepatitis (NASH) Treatment, market overview.
Chapter 2: Global Non-Alcoholic Steatohepatitis (NASH) Treatment market size in revenue.
Chapter 3: Detailed analysis of Non-Alcoholic Steatohepatitis (NASH) Treatment company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Non-Alcoholic Steatohepatitis (NASH) Treatment in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Non-Alcoholic Steatohepatitis (NASH) Treatment Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Non-Alcoholic Steatohepatitis (NASH) Treatment Overall Market Size
2.1 Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size: 2022 VS 2030
2.2 Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size, Prospects & Forecasts: 2018-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Non-Alcoholic Steatohepatitis (NASH) Treatment Players in Global Market
3.2 Top Global Non-Alcoholic Steatohepatitis (NASH) Treatment Companies Ranked by Revenue
3.3 Global Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue by Companies
3.4 Top 3 and Top 5 Non-Alcoholic Steatohepatitis (NASH) Treatment Companies in Global Market, by Revenue in 2022
3.5 Global Companies Non-Alcoholic Steatohepatitis (NASH) Treatment Product Type
3.6 Tier 1, Tier 2 and Tier 3 Non-Alcoholic Steatohepatitis (NASH) Treatment Players in Global Market
3.6.1 List of Global Tier 1 Non-Alcoholic Steatohepatitis (NASH) Treatment Companies
3.6.2 List of Global Tier 2 and Tier 3 Non-Alcoholic Steatohepatitis (NASH) Treatment Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size Markets, 2022 & 2030
4.1.2 Off-Label
4.1.3 Therapeutic
4.2 By Type - Global Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue & Forecasts
4.2.1 By Type - Global Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, 2018-2023
4.2.2 By Type - Global Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, 2024-2030
4.2.3 By Type - Global Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue Market Share, 2018-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size, 2022 & 2030
5.1.2 Hospital Pharmacy
5.1.3 Online Provider
5.1.4 Retail Pharmacy
5.2 By Application - Global Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue & Forecasts
5.2.1 By Application - Global Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, 2018-2023
5.2.2 By Application - Global Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, 2024-2030
5.2.3 By Application - Global Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue Market Share, 2018-2030
6 Sights by Region
6.1 By Region - Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size, 2022 & 2030
6.2 By Region - Global Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue & Forecasts
6.2.1 By Region - Global Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, 2018-2023
6.2.2 By Region - Global Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, 2024-2030
6.2.3 By Region - Global Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue Market Share, 2018-2030
6.3 North America
6.3.1 By Country - North America Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, 2018-2030
6.3.2 US Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size, 2018-2030
6.3.3 Canada Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size, 2018-2030
6.3.4 Mexico Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size, 2018-2030
6.4 Europe
6.4.1 By Country - Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, 2018-2030
6.4.2 Germany Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size, 2018-2030
6.4.3 France Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size, 2018-2030
6.4.4 U.K. Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size, 2018-2030
6.4.5 Italy Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size, 2018-2030
6.4.6 Russia Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size, 2018-2030
6.4.7 Nordic Countries Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size, 2018-2030
6.4.8 Benelux Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size, 2018-2030
6.5 Asia
6.5.1 By Region - Asia Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, 2018-2030
6.5.2 China Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size, 2018-2030
6.5.3 Japan Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size, 2018-2030
6.5.4 South Korea Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size, 2018-2030
6.5.5 Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size, 2018-2030
6.5.6 India Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size, 2018-2030
6.6 South America
6.6.1 By Country - South America Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, 2018-2030
6.6.2 Brazil Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size, 2018-2030
6.6.3 Argentina Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size, 2018-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, 2018-2030
6.7.2 Turkey Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size, 2018-2030
6.7.3 Israel Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size, 2018-2030
6.7.4 Saudi Arabia Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size, 2018-2030
6.7.5 UAE Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size, 2018-2030
7 Non-Alcoholic Steatohepatitis (NASH) Treatment Companies Profiles
7.1 Allergan Plc (Tobira)
7.1.1 Allergan Plc (Tobira) Company Summary
7.1.2 Allergan Plc (Tobira) Business Overview
7.1.3 Allergan Plc (Tobira) Non-Alcoholic Steatohepatitis (NASH) Treatment Major Product Offerings
7.1.4 Allergan Plc (Tobira) Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue in Global Market (2018-2023)
7.1.5 Allergan Plc (Tobira) Key News & Latest Developments
7.2 Bristol Myers Squibb
7.2.1 Bristol Myers Squibb Company Summary
7.2.2 Bristol Myers Squibb Business Overview
7.2.3 Bristol Myers Squibb Non-Alcoholic Steatohepatitis (NASH) Treatment Major Product Offerings
7.2.4 Bristol Myers Squibb Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue in Global Market (2018-2023)
7.2.5 Bristol Myers Squibb Key News & Latest Developments
7.3 Galmed Pharmaceuticals
7.3.1 Galmed Pharmaceuticals Company Summary
7.3.2 Galmed Pharmaceuticals Business Overview
7.3.3 Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Treatment Major Product Offerings
7.3.4 Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue in Global Market (2018-2023)
7.3.5 Galmed Pharmaceuticals Key News & Latest Developments
7.4 Genfit SA
7.4.1 Genfit SA Company Summary
7.4.2 Genfit SA Business Overview
7.4.3 Genfit SA Non-Alcoholic Steatohepatitis (NASH) Treatment Major Product Offerings
7.4.4 Genfit SA Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue in Global Market (2018-2023)
7.4.5 Genfit SA Key News & Latest Developments
7.5 Gilead Sciences, Inc.
7.5.1 Gilead Sciences, Inc. Company Summary
7.5.2 Gilead Sciences, Inc. Business Overview
7.5.3 Gilead Sciences, Inc. Non-Alcoholic Steatohepatitis (NASH) Treatment Major Product Offerings
7.5.4 Gilead Sciences, Inc. Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue in Global Market (2018-2023)
7.5.5 Gilead Sciences, Inc. Key News & Latest Developments
7.6 Intercept Pharmaceuticals, Inc.
7.6.1 Intercept Pharmaceuticals, Inc. Company Summary
7.6.2 Intercept Pharmaceuticals, Inc. Business Overview
7.6.3 Intercept Pharmaceuticals, Inc. Non-Alcoholic Steatohepatitis (NASH) Treatment Major Product Offerings
7.6.4 Intercept Pharmaceuticals, Inc. Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue in Global Market (2018-2023)
7.6.5 Intercept Pharmaceuticals, Inc. Key News & Latest Developments
7.7 Zydus Cadila
7.7.1 Zydus Cadila Company Summary
7.7.2 Zydus Cadila Business Overview
7.7.3 Zydus Cadila Non-Alcoholic Steatohepatitis (NASH) Treatment Major Product Offerings
7.7.4 Zydus Cadila Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue in Global Market (2018-2023)
7.7.5 Zydus Cadila Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Non-Alcoholic Steatohepatitis (NASH) Treatment Market Opportunities & Trends in Global Market
Table 2. Non-Alcoholic Steatohepatitis (NASH) Treatment Market Drivers in Global Market
Table 3. Non-Alcoholic Steatohepatitis (NASH) Treatment Market Restraints in Global Market
Table 4. Key Players of Non-Alcoholic Steatohepatitis (NASH) Treatment in Global Market
Table 5. Top Non-Alcoholic Steatohepatitis (NASH) Treatment Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue Share by Companies, 2018-2023
Table 8. Global Companies Non-Alcoholic Steatohepatitis (NASH) Treatment Product Type
Table 9. List of Global Tier 1 Non-Alcoholic Steatohepatitis (NASH) Treatment Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Non-Alcoholic Steatohepatitis (NASH) Treatment Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, (US$, Mn), 2022 & 2030
Table 12. By Type - Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue in Global (US$, Mn), 2024-2030
Table 14. By Application ? Global Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, (US$, Mn), 2022 & 2030
Table 15. By Application - Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue in Global (US$, Mn), 2024-2030
Table 17. By Region ? Global Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, (US$, Mn), 2022 & 2030
Table 18. By Region - Global Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue (US$, Mn), 2024-2030
Table 20. By Country - North America Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, (US$, Mn), 2024-2030
Table 22. By Country - Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, (US$, Mn), 2024-2030
Table 24. By Region - Asia Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, (US$, Mn), 2024-2030
Table 26. By Country - South America Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, (US$, Mn), 2024-2030
Table 28. By Country - Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, (US$, Mn), 2024-2030
Table 30. Allergan Plc (Tobira) Company Summary
Table 31. Allergan Plc (Tobira) Non-Alcoholic Steatohepatitis (NASH) Treatment Product Offerings
Table 32. Allergan Plc (Tobira) Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue (US$, Mn) & (2018-2023)
Table 33. Allergan Plc (Tobira) Key News & Latest Developments
Table 34. Bristol Myers Squibb Company Summary
Table 35. Bristol Myers Squibb Non-Alcoholic Steatohepatitis (NASH) Treatment Product Offerings
Table 36. Bristol Myers Squibb Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue (US$, Mn) & (2018-2023)
Table 37. Bristol Myers Squibb Key News & Latest Developments
Table 38. Galmed Pharmaceuticals Company Summary
Table 39. Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Treatment Product Offerings
Table 40. Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue (US$, Mn) & (2018-2023)
Table 41. Galmed Pharmaceuticals Key News & Latest Developments
Table 42. Genfit SA Company Summary
Table 43. Genfit SA Non-Alcoholic Steatohepatitis (NASH) Treatment Product Offerings
Table 44. Genfit SA Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue (US$, Mn) & (2018-2023)
Table 45. Genfit SA Key News & Latest Developments
Table 46. Gilead Sciences, Inc. Company Summary
Table 47. Gilead Sciences, Inc. Non-Alcoholic Steatohepatitis (NASH) Treatment Product Offerings
Table 48. Gilead Sciences, Inc. Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue (US$, Mn) & (2018-2023)
Table 49. Gilead Sciences, Inc. Key News & Latest Developments
Table 50. Intercept Pharmaceuticals, Inc. Company Summary
Table 51. Intercept Pharmaceuticals, Inc. Non-Alcoholic Steatohepatitis (NASH) Treatment Product Offerings
Table 52. Intercept Pharmaceuticals, Inc. Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue (US$, Mn) & (2018-2023)
Table 53. Intercept Pharmaceuticals, Inc. Key News & Latest Developments
Table 54. Zydus Cadila Company Summary
Table 55. Zydus Cadila Non-Alcoholic Steatohepatitis (NASH) Treatment Product Offerings
Table 56. Zydus Cadila Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue (US$, Mn) & (2018-2023)
Table 57. Zydus Cadila Key News & Latest Developments
List of Figures
Figure 1. Non-Alcoholic Steatohepatitis (NASH) Treatment Segment by Type in 2022
Figure 2. Non-Alcoholic Steatohepatitis (NASH) Treatment Segment by Application in 2022
Figure 3. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size: 2022 VS 2030 (US$, Mn)
Figure 6. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, 2018-2030 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue in 2022
Figure 8. By Type - Global Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue Market Share, 2018-2030
Figure 9. By Application - Global Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue Market Share, 2018-2030
Figure 10. By Type - Global Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, (US$, Mn), 2022 & 2030
Figure 11. By Type - Global Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue Market Share, 2018-2030
Figure 12. By Application - Global Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, (US$, Mn), 2022 & 2030
Figure 13. By Application - Global Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue Market Share, 2018-2030
Figure 14. By Region - Global Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue Market Share, 2018-2030
Figure 15. By Country - North America Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue Market Share, 2018-2030
Figure 16. US Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, (US$, Mn), 2018-2030
Figure 17. Canada Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, (US$, Mn), 2018-2030
Figure 18. Mexico Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, (US$, Mn), 2018-2030
Figure 19. By Country - Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue Market Share, 2018-2030
Figure 20. Germany Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, (US$, Mn), 2018-2030
Figure 21. France Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, (US$, Mn), 2018-2030
Figure 22. U.K. Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, (US$, Mn), 2018-2030
Figure 23. Italy Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, (US$, Mn), 2018-2030
Figure 24. Russia Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, (US$, Mn), 2018-2030
Figure 25. Nordic Countries Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, (US$, Mn), 2018-2030
Figure 26. Benelux Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, (US$, Mn), 2018-2030
Figure 27. By Region - Asia Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue Market Share, 2018-2030
Figure 28. China Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, (US$, Mn), 2018-2030
Figure 29. Japan Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, (US$, Mn), 2018-2030
Figure 30. South Korea Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, (US$, Mn), 2018-2030
Figure 31. Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, (US$, Mn), 2018-2030
Figure 32. India Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, (US$, Mn), 2018-2030
Figure 33. By Country - South America Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue Market Share, 2018-2030
Figure 34. Brazil Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, (US$, Mn), 2018-2030
Figure 35. Argentina Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, (US$, Mn), 2018-2030
Figure 36. By Country - Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue Market Share, 2018-2030
Figure 37. Turkey Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, (US$, Mn), 2018-2030
Figure 38. Israel Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, (US$, Mn), 2018-2030
Figure 39. Saudi Arabia Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, (US$, Mn), 2018-2030
Figure 40. UAE Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue, (US$, Mn), 2018-2030
Figure 41. Allergan Plc (Tobira) Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Bristol Myers Squibb Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Genfit SA Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Gilead Sciences, Inc. Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Intercept Pharmaceuticals, Inc. Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Zydus Cadila Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
